Daiichi Sankyo Company (4568) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
Q1 FY2026 revenue rose 21.1% year-over-year to JPY 574.7 billion, driven by strong sales of ENHERTU and DATROWAY and favorable foreign exchange effects.
Core operating profit increased 6.2% to JPY 107.3 billion, but operating profit declined 12.0% to JPY 85.1 billion due to higher restructuring expenses in the EU Specialty Business Unit.
Profit attributable to owners dropped 19.7% to JPY 68.6 billion, mainly due to higher income taxes and financial expenses.
Correction of FY2025 results due to booking errors in accounts payable and SG&A; internal controls deemed effective overall, with measures underway to prevent recurrence.
Total comprehensive income rose 28.5% to JPY 87.7 billion, reflecting positive currency translation differences.
Financial highlights
Q1 FY2026 revenue increased by JPY 100.1 billion year-over-year, with a JPY 41.9 billion positive forex impact.
Core operating profit up JPY 6.3 billion (6.2% YoY) to JPY 107.3 billion; operating profit down JPY 11.6 billion (12.2% YoY) to JPY 85.1 billion.
Cost of sales increased 43.9% YoY to JPY 126.0 billion, and SG&A expenses rose 25.5% to JPY 226.0 billion, mainly from higher profit sharing with AstraZeneca.
R&D expenses grew 9.0% to JPY 115.5 billion, reflecting intensified investment in ADCs and pipeline projects.
Profit attributable to owners down JPY 16.9 billion YoY to JPY 68.6 billion; EPS down 18.1% to JPY 37.72.
Outlook and guidance
FY2026 revenue forecast raised by JPY 60 billion from May to JPY 2.34 trillion, reflecting yen depreciation and strong ENHERTU sales.
Core operating profit guidance unchanged at JPY 360 billion; operating profit and profit before tax raised by JPY 5 billion each.
Profit attributable to owners forecast at JPY 251 billion, reflecting tax deduction adjustments and higher expected income taxes.
Annual dividend forecast increased to JPY 100 per share, up JPY 22 from the prior year.
FY2026 EPS forecast revised down to JPY 137.94 due to higher tax rate and increased SG&A expenses.
Latest events from Daiichi Sankyo Company
- Oncology and ENHERTU sales drove strong revenue and profit growth, with ongoing market and approval risks.4568
Q1 20254 Aug 2026 - ADC-based regimens show strong efficacy and safety in multiple cancers, with new biomarkers advancing.4568
WCLC/ESMO 2024 Conference4 Aug 2026 - T-DXd delivers robust efficacy and safety in HER2-low/ultralow breast cancer, expanding treatment options.4568
Status Update9 Jul 2026 - ENHERTU® and DXd ADCs drive clinical, regulatory, and supply advances, expanding global impact.4568
Status Update9 Jul 2026 - Multiple new oncology launches and clinical catalysts set to triple eligible patients by 2026.4568
Status Update9 Jul 2026 - Oncology-driven revenue and profit growth, robust outlook, and higher dividend planned.4568
Q3 20269 Jul 2026 - Oncology-driven revenue growth offset by higher costs and revised profit guidance.4568
Q2 20268 Jul 2026 - Record profit and revenue growth driven by oncology, with higher dividends and buybacks ahead.4568
Q4 20258 Jul 2026 - Oncology-driven revenue and profit growth offset by one-time expenses, with strong future targets.4568
Q4 20268 Jul 2026